Zenas BioPharma, Inc. (ZBIO)
Automate Your Wheel Strategy on ZBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including ZBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZBIO
- Rev/Share 0.3588
- Book/Share 6.8017
- PB 1.3688
- Debt/Equity 0.0043
- CurrentRatio 6.4684
- ROIC -0.6097
- MktCap 389476244.0
- FreeCF/Share -3.2954
- PFCF -2.8274
- PE -2.388
- Debt/Assets 0.0037
- DivYield 0
- ROE -0.9767
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ZBIO | Wedbush | -- | Outperform | -- | $35 | March 20, 2025 |
| Initiation | ZBIO | Wolfe Research | -- | Outperform | -- | $19 | Feb. 4, 2025 |
| Initiation | ZBIO | H.C. Wainwright | -- | Buy | -- | $30 | Dec. 16, 2024 |
| Initiation | ZBIO | Morgan Stanley | -- | Overweight | -- | $40 | Oct. 8, 2024 |
| Initiation | ZBIO | Jefferies | -- | Buy | -- | $35 | Oct. 8, 2024 |
| Initiation | ZBIO | Guggenheim | -- | Buy | -- | $45 | Oct. 8, 2024 |
| Initiation | ZBIO | Citigroup | -- | Buy | -- | $27 | Oct. 8, 2024 |
News
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public.
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 24, 2025 / WHY: New York, N.Y., March 24, 2025.
Read More
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Published: March 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public. So What: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
About Zenas BioPharma, Inc. (ZBIO)
- IPO Date 2024-09-13
- Website https://zenasbio.com
- Industry Biotechnology
- CEO Mr. Leon Oliver Moulder Jr., M.B.A.
- Employees 130